Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCE-MRI with Dotarem for Sorafenib Response in HCC
NCT01806740Phase 4Terminated
- Sponsor
- Guerbet
- Start
- May 2013
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of gadoterate meglumine in hepatocellular carcinoma (HCC), sponsored by Guerbet. Primary endpoint: Correlation Coefficient Between DCE-MRI Perfusion Parameters and the Response of Target Lesions to Sorafenib at 3 months. Started May 2013; status: terminated.
02
Drugs
gadoterate meglumine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01806740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01806740.